• Citer

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

par Gatell, Jose;Guaraldi, Giovanni Paolo;Masia, Mar;Gompels, Mark;De Wit, Stéphane ;Florence, Eric;Esser, Stefan;Raffi, François;Pozniak, Anton Louis;Assoumou, Lambert;Moyle, Graeme;Waters, Laura;Johnson, Margaret;Domingo, Pere;Fox, Julie;Martinez, Esteban;Stellbrink, Hans-Jurgen
Référence AIDS, 31, 18, page (2503-2514)
Publication Publié, 2017-11

Article révisé par les pairs

• Détails
• Contenu

Titre:	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
Auteur:	Gatell, Jose; Guaraldi, Giovanni Paolo; Masia, Mar; Gompels, Mark; De Wit, Stéphane; Florence, Eric; Esser, Stefan; Raffi, François; Pozniak, Anton Louis; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Martinez, Esteban; Stellbrink, Hans-Jurgen
Informations sur la publication:	AIDS, 31, 18, page (2503-2514)
Statut de publication:	Publié, 2017-11
Sujet CREF:	Immunologie
	Pathologie maladies infectieuses
	Allergie et immunopathologie
Mots-clés:	cardiovascular risk
	cholesterol
	dolutegravir
	HIV-1
	lipids
	protease inhibitors
	randomized clinical trials
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0269-9370
	info:doi/10.1097/QAD.0000000000001675
	info:scp/85033785687